Ampersand Capital Partners
Ampersand Capital Partners is a healthcare and life sciences-focused private equity firm with long-standing experience in middle-market investing.
- Healthcare and life sciences private equity investment firm
- Healthcare & Life Sciences PEF
- Tier II
Overview
Ampersand Capital Partners is a healthcare and life sciences-focused private equity firm with long-standing experience in middle-market investing. Its principal areas include life sciences tools, diagnostics, pharmaceutical services, contract development and manufacturing, laboratory products, and related healthcare technologies.
The firm’s life sciences orientation provides an important counterweight to healthcare lists dominated by provider services. Businesses serving research, development, testing, and production require specialized assessment of scientific relevance, quality systems, customer relationships, regulatory requirements, and technical differentiation. Within The Economy Wiki, the firm is connected to the Healthcare & Life Sciences PEF market category.
Firm facts
| Institution | Ampersand Capital Partners |
| Type | Healthcare and life sciences private equity investment firm |
| Headquarters | Boston, United States |
| Founded | 1988 |
| Primary ranking focus | Healthcare & Life Sciences PEF |
| Highest 2026 tier | Tier II |
Activities and investment capabilities
Ampersand typically partners with companies that possess an established commercial foundation but require capital, strategic guidance, acquisition support, or operational resources to scale. Its sector network and repeated experience across technical healthcare markets support informed platform development.
Healthcare investing
Equity investment across healthcare services, products and technology.
Life sciences exposure
Capital for pharmaceutical, biotechnology, medtech and outsourced-service platforms.
Sector value creation
Support informed by regulation, reimbursement, clinical workflows and market access.
Strategy and transaction coverage
Strategy and sector coverage
Healthcare services; life sciences; pharmaceuticals; medtech; diagnostics; healthcare IT
Transaction and ownership contexts
Buyouts; growth investments; recapitalizations; platform formation; add-on acquisitions
Market position
Ampersand fits Tier II because it is an established specialist with a clear standalone identity, sustained life sciences relevance, and a differentiated record in the infrastructure supporting scientific and medical innovation.
Ampersand Capital Partners is assessed within the Healthcare & Life Sciences PEF framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
Ampersand Capital Partners is recognized Tier II in Top 30 Healthcare & Life Sciences PEF 2026. The ranking compares firms by institutional relevance, specialist capability, investment activity, operating depth and market positioning. Comparable-firm links below support navigation and do not imply that every institution competes for every transaction or asset.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through Ampersand Capital Partners’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to Ampersand Capital Partners as the public-facing investment organization. Individual funds, management companies, advisers and regulated entities may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | Ampersand Capital Partners |
| Headquarters | Boston, United States |
| Public website | ampersandcapital.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the investment, diligence, financing and value-creation themes relevant to this firm:
- The Mid-Market Advantage in Healthcare Private Equity
- Middle-Market Private Equity: Returns, Scale and Manager Selection
- Private Equity Technology Due Diligence in the AI Era
